TransCode Therapeutics has announced the commencement of its Phase I clinical study of TTX-MC138, a therapeutic candidate designed to potentially treat patients with metastatic solid cancers.
The trial has activated two clinical sites, with patient enrolment expected to start within the current quarter.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company may expand up to five clinical trial sites, all expected to be operational this quarter.
This multicentre, open-label trial aims to collect vital data on the safety of TTX-MC138 in patients with diverse metastatic solid cancers and may also provide preliminary evidence of its clinical efficacy.
The study is structured into two parts: an initial dose-escalation phase to assess the safety and tolerability of increasing doses of TTX-MC138, followed by a dose-expansion phase.
During the dose-expansion phase, researchers will further investigate its safety, tolerability and anti-tumour activity in specific tumour types.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThese will be selected based on the initial findings from the dose-escalation phase.
Participants will continue treatment until they experience a dose-limiting toxicity (DLT), an adverse event (AE) leading to unacceptable toxicity, progression of disease or withdrawal of consent.
TransCode Therapeutics Operations senior vice-president Sue Duggan said: “We are thrilled to have garnered such high interest in TTX-MC138 from eminent oncologists working in some of the most respected clinical trial sites in the country.
“Advancing breakthrough RNA therapeutics science in the clinic is our primary goal as a biotechnology company at the cusp of innovative technology.”
In August last year, the company dosed the first subject in a first-in-human Phase 0 clinical trial of radiolabelled TTX-MC138 to treat advanced solid tumours.
The trial was designed to quantify the amount of TTX-MC138 delivered to metastatic lesions and assess the pharmacokinetics of the candidate.
